So, this trial was the largest trial that's ever been conducted in premenopausal women with hormone receptor positive breast cancer. There was the important difference between this trial and other trials.
Thank you for your interest in our research. We've got no conflicts of interest to disclose for this research. I would like to point out for those of you, who are interested in some more information about our study after the meeting, that I'm pleased to say that I have my study co-chair Jeanne Fleming in the audience. I also have Meredith Regan, who did the trial analysis here.
I'm 40. I've had two breast biopsies, one small and one large. My cells were abnormal, but not breast cancer. My choice is to start Tamoxifen or not. Should I?
One of the things that really interested me at San Antonio in 2018 was that we saw data looking at using Tamoxifen for women with ductal carcinoma in situ or the high-risk precancerous lesions, like lobular carcinoma in situ or atypical ductal hyperplasia. And it asked the question of Tamoxifen at five milligrams versus no therapy.
“Mothers have seen their children grow up. Grandmothers have seen their grandchildren grow up. That never happened before 1975, when chemotherapy was going to cure everything, and it didn't.
Hello everyone. I hope that everyone is safe during these crazy times and that everyone's social distancing. We're all doing the right thing and pretty soon, hopefully, the over there is. I would do a quick chat on Tamoxifen. That's the drug that some women go on after breast cancer. That is a maintenance drug and they'll prevent breast cancer to come back with the help of the drug.
So, to shine UK we've adopted a slightly different approach to the drug development, and we're looking at repurposing, which is when you take a drug that's already been approved for use in a different disease like cancer, and you test it to see if it's going to have efficacy in Duchenne muscular dystrophy.
Many of the European agencies have recommended that women should consider taking the drug for an extra five years. And without this test we know that we can't predict exactly who is going to benefit for the extra five years. So, as we have in the past, we tend to offer this to all women. Our many oncologists do that.
Page: 3 from 4